Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Bank of Nova Scotia

Bank of Nova Scotia lessened its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 73.2% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 67,666 shares of the biotechnology company's stock after selling 185,102 shares during the quarter. Bank of Nova Scotia owned approximately 0.07% of Sarepta Therapeutics worth $8,228,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank bought a new position in shares of Sarepta Therapeutics in the fourth quarter worth about $126,315,000. Brandywine Global Investment Management LLC purchased a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $22,613,000. Swedbank AB purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $16,706,000. Vanguard Group Inc. lifted its holdings in shares of Sarepta Therapeutics by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock worth $1,104,701,000 after buying an additional 117,904 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its holdings in Sarepta Therapeutics by 16,717.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company's stock worth $10,602,000 after acquiring an additional 84,926 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded down $0.21 during mid-day trading on Tuesday, hitting $54.42. The stock had a trading volume of 2,215,088 shares, compared to its average volume of 1,395,804. The firm has a market cap of $5.28 billion, a PE ratio of 43.54 and a beta of 0.93. The company's 50-day simple moving average is $86.82 and its 200-day simple moving average is $109.61. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a fifty-two week low of $48.01 and a fifty-two week high of $173.25.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on SRPT shares. Royal Bank of Canada lowered Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and cut their target price for the company from $161.00 to $87.00 in a research note on Monday, March 31st. HC Wainwright upgraded Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 price target on the stock in a research note on Wednesday, April 2nd. Wells Fargo & Company assumed coverage on shares of Sarepta Therapeutics in a research note on Friday. They issued an "overweight" rating and a $115.00 price objective on the stock. Morgan Stanley decreased their price target on Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating for the company in a report on Friday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Six research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $161.83.

Insider Activity

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.